Psylo's Revolutionary Approach to Mental Health Treatment Leading the Way in Biotechnology Innovation
June 5, 2024, 9:34 am
Psylo, a cutting-edge biotechnology company headquartered in San Diego, California, is making significant strides in the realm of mental health treatment with their groundbreaking approach to developing next-generation neuroplastogens. Recently securing a substantial $8 million in seed funding, Psylo is on a mission to advance their flagship non-hallucinogenic 5-HT2A agonist, known as PSYLO-100X, for the treatment of depression and various other mental health disorders.
Under the leadership of CEO Joshua Ismin and Chief Scientific Officer Samuel Banister, Psylo has established itself as a trailblazer in the field of biotechnology, with a focus on utilizing innovative translational methods to bring about transformative advancements in mental health care. The recent infusion of capital from leading investors such as Tenmile, Palo Santo, Focalpoint Ventures, Mystic Ventures, and Gaingels underscores the strong confidence in Psylo's unique approach and the promising therapeutic potential of their pipeline.
Joshua Ismin, in a statement following the funding announcement, expressed his enthusiasm for the future of Psylo, highlighting the company's commitment to developing a non-hallucinogenic candidate that can be safely administered at home without clinical supervision. This approach, he believes, will play a crucial role in addressing the widespread mental health crisis and reaching a broader patient population in need of effective treatment options.
PSYLO-100X, Psylo's flagship compound, sets itself apart from traditional psychedelics by eliciting neuronal remodeling without inducing hallucinatory effects. This breakthrough compound has demonstrated antidepressant-like effects in vivo and has shown promise in promoting neuroplasticity in vitro. Importantly, PSYLO-100X avoids activation at the 5-HT2B receptor, a critical safety feature that mitigates the risk of cardiotoxicity associated with receptor activation.
Dr. Samuel Banister, Psylo's esteemed Chief Scientific Officer, emphasized the significant progress made in the development of PSYLO-100X after three years of rigorous drug discovery efforts. He highlighted the compound's non-tryptamine, non-phenethylamine composition and its promising preclinical profile, marking a substantial leap forward in the quest for safer and more effective mental health treatments.
Looking ahead, Psylo plans to utilize the Series Seed funds to further invest in their drug discovery platform and advance PSYLO-100X through IND enabling studies. The ultimate goal is to initiate first-in-human clinical trials in 2025, paving the way for the potential widespread adoption of this innovative treatment approach.
Founded in Australia and recently restructured as a US Delaware C-corp, Psylo has established labs at the University of Colorado Boulder and the University of New South Wales in Sydney. Their commitment to leveraging cutting-edge science and innovative therapeutic approaches underscores their dedication to transforming the mental health landscape and improving the lives of millions worldwide.
In conclusion, Psylo's pioneering work in neuroplastogens represents a significant step forward in the field of mental health treatment. With their revolutionary approach and unwavering commitment to innovation, Psylo is poised to lead the way in reshaping the future of mental health care and providing hope for those in need of effective and accessible treatment options.
Under the leadership of CEO Joshua Ismin and Chief Scientific Officer Samuel Banister, Psylo has established itself as a trailblazer in the field of biotechnology, with a focus on utilizing innovative translational methods to bring about transformative advancements in mental health care. The recent infusion of capital from leading investors such as Tenmile, Palo Santo, Focalpoint Ventures, Mystic Ventures, and Gaingels underscores the strong confidence in Psylo's unique approach and the promising therapeutic potential of their pipeline.
Joshua Ismin, in a statement following the funding announcement, expressed his enthusiasm for the future of Psylo, highlighting the company's commitment to developing a non-hallucinogenic candidate that can be safely administered at home without clinical supervision. This approach, he believes, will play a crucial role in addressing the widespread mental health crisis and reaching a broader patient population in need of effective treatment options.
PSYLO-100X, Psylo's flagship compound, sets itself apart from traditional psychedelics by eliciting neuronal remodeling without inducing hallucinatory effects. This breakthrough compound has demonstrated antidepressant-like effects in vivo and has shown promise in promoting neuroplasticity in vitro. Importantly, PSYLO-100X avoids activation at the 5-HT2B receptor, a critical safety feature that mitigates the risk of cardiotoxicity associated with receptor activation.
Dr. Samuel Banister, Psylo's esteemed Chief Scientific Officer, emphasized the significant progress made in the development of PSYLO-100X after three years of rigorous drug discovery efforts. He highlighted the compound's non-tryptamine, non-phenethylamine composition and its promising preclinical profile, marking a substantial leap forward in the quest for safer and more effective mental health treatments.
Looking ahead, Psylo plans to utilize the Series Seed funds to further invest in their drug discovery platform and advance PSYLO-100X through IND enabling studies. The ultimate goal is to initiate first-in-human clinical trials in 2025, paving the way for the potential widespread adoption of this innovative treatment approach.
Founded in Australia and recently restructured as a US Delaware C-corp, Psylo has established labs at the University of Colorado Boulder and the University of New South Wales in Sydney. Their commitment to leveraging cutting-edge science and innovative therapeutic approaches underscores their dedication to transforming the mental health landscape and improving the lives of millions worldwide.
In conclusion, Psylo's pioneering work in neuroplastogens represents a significant step forward in the field of mental health treatment. With their revolutionary approach and unwavering commitment to innovation, Psylo is poised to lead the way in reshaping the future of mental health care and providing hope for those in need of effective and accessible treatment options.